Want to see AU:NOX full AI Analyst Report?
Top Page
Noxopharm Ltd.
(Sydney:NOX)
Select Model
Select Model
Rating:46Neutral
Price Target:
AU$0.07
▼(-30.00% Downside)
Action:Reiterated
Date:08/30/26
The score is primarily held down by weak financial performance—ongoing losses and cash burn alongside a deteriorated balance sheet (negative equity and higher debt). Technical indicators are broadly neutral and provide only modest support, while valuation is constrained by a negative P/E and no dividend yield data.
Positive Factors
Oncology R&D Focus
A focused oncology pipeline gives Noxopharm exposure to substantial unmet medical needs and potential advances in cancer treatment. Approaches that improve radiotherapy or other anti-cancer modalities could support differentiated product opportunities if development successfully demonstrates clinical benefit.
Negative Factors
Persistent Losses
Persistent operating and net losses show that Noxopharm has not yet reached commercial profitability, leaving earnings dependent on successful future development and commercialization. Continued losses can consume capital, constrain investment choices, and make durable self-funded growth difficult over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Oncology R&D Focus
A focused oncology pipeline gives Noxopharm exposure to substantial unmet medical needs and potential advances in cancer treatment. Approaches that improve radiotherapy or other anti-cancer modalities could support differentiated product opportunities if development successfully demonstrates clinical benefit.
Read all positive factors
Noxopharm Ltd. (NOX) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$23.35M
Dividend YieldN/A
Average Volume (3M)86.86K
Price to Earnings (P/E)―
Beta (1Y)1.11
Revenue GrowthN/A
EPS Growth8.98%
CountryAU
Employees8
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.02
Shares Outstanding307,237,950
10 Day Avg. Volume83,274
30 Day Avg. Volume86,858
Financial Highlights & Ratios
PEG Ratio0.57
Price to Book (P/B)-7.08
Price to Sales (P/S)17.83
P/FCF Ratio-9.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Noxopharm Ltd. Business Overview & Revenue Model
Company Description
Noxopharm Limited is an Australian drug development company with an international reach, focused on pioneering new treatment options for a range of solid tumor cancers and septic shock. Its primary asset, Veyonda, functions as an adjuvant therapy ...
How the Company Makes Money
null...
Noxopharm Ltd. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
12
Very Negative
Cash Flow
22
Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.45M | 2.82M | 2.40M | 6.01M | 5.43M |
| Gross Profit | 1.45M | -1.45M | -534.81K | 5.86M | 5.17M |
| EBITDA | -3.40M | -5.38M | -5.95M | -20.85M | -23.70M |
| Net Income | -4.46M | -4.88M | -3.58M | -15.06M | -18.67M |
Balance Sheet | |||||
| Total Assets | 1.84M | 4.58M | 6.78M | 10.13M | 26.59M |
| Cash, Cash Equivalents and Short-Term Investments | 293.57K | 1.55M | 2.32M | 3.01M | 14.01M |
| Total Debt | 4.57M | 2.48M | 0.00 | 0.00 | 160.62K |
| Total Liabilities | 5.48M | 3.89M | 1.29M | 1.06M | 2.48M |
| Stockholders Equity | -3.65M | 689.96K | 5.50M | 9.07M | 24.12M |
Cash Flow | |||||
| Free Cash Flow | -2.71M | -5.82M | -684.31K | -10.95M | -13.73M |
| Operating Cash Flow | -2.71M | -5.82M | -684.31K | -10.95M | -13.73M |
| Investing Cash Flow | 0.00 | 2.48M | 0.00 | 123.51K | 0.00 |
| Financing Cash Flow | 1.45M | 2.60M | 0.00 | -178.09K | 975.73K |
Noxopharm Ltd. Technical Analysis
Negative
0.10
Price Trends
0.09
Negative
0.08
Negative
0.08
Positive
Market Momentum
>-0.01
Positive
45.60
Neutral
9.84
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:NOX, the sentiment is Negative. The current price of 0.1 is above the 20-day moving average (MA) of 0.08, above the 50-day MA of 0.09, and above the 200-day MA of 0.08, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 45.60 is Neutral, neither overbought nor oversold. The STOCH value of 9.84 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:NOX.
Noxopharm Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | AU$5.60B | 119.18 | 7.11% | ― | 26.66% | 179.32% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$411.74M | -33.93 | -36.95% | ― | ― | -125.09% | |
46 Neutral | AU$23.35M | -4.97 | 186.62% | ― | ― | 8.98% | |
45 Neutral | AU$71.50M | -9.86 | -44.93% | ― | ― | 25.27% | |
45 Neutral | AU$850.63M | -7.86 | -51.15% | ― | ― | -44.83% | |
42 Neutral | AU$39.04M | -0.58 | -144.24% | ― | -23.82% | 12.36% |
* Healthcare Sector Average
AU:NOX
Noxopharm Ltd.
0.07
-0.03
-29.00%
AU:PTX
Prescient Therapeutics Limited
0.07
0.03
70.00%
AU:TLX
Telix Pharmaceuticals
16.25
2.65
19.49%
AU:RAC
Race Oncology Ltd.
2.13
0.41
23.84%
AU:CU6
Clarity Pharmaceuticals Ltd.
2.27
-0.88
-27.94%
AU:RAD
Radiopharm Theranostics Limited
0.01
-0.02
-65.52%
Noxopharm Ltd. Corporate Events
Noxopharm outlines precision therapy pipeline and clarifies trial links
Sep 3, 2026
Noxopharm has released an investor presentation outlining its development focus on precision therapies targeting chronic inflammation, autoimmune conditions and cancer, highlighting its SOF-SKN, SOF-CAN and SOF-VAC programs. The company emphasises...
Noxopharm’s Sofra Oligos Show Promise in Reducing mRNA Vaccine Reactogenicity
Sep 1, 2026
Noxopharm has reported promising data on its novel oligonucleotides from the Sofra platform, presented by CSL at the International Society for Respiratory Viruses’ Options for the Control of Influenza XIII Conference in Washington, D.C. The ...
Noxopharm Narrows Annual Loss but Net Tangible Assets Turn Negative
Aug 28, 2026
Noxopharm Limited reported a reduced annual loss of $4.46 million for the year ended 30 June 2026, an 8.8% improvement on the prior year’s $4.88 million loss, indicating modest progress in narrowing its deficit. The company did not declare o...
Noxopharm Preclinical Data Bolsters Sofra Immuno-Oncology Platform
Aug 25, 2026
Noxopharm has reported new preclinical data showing its Sofra technology can activate immune cells in response to dying cancer cells, strengthening its immuno-oncology proposition. In studies with the Hudson Institute of Medical Research, signific...
Noxopharm Data Validate TLR8-Targeted Oligonucleotide Cancer Strategy
Aug 3, 2026
Noxopharm has reported new preclinical data showing its synthetic RNA oligonucleotides can convert normally immune-silent cellular RNA into a potent trigger for Toll-like receptor 8, a key immune sensor. In vitro, combining total cellular RNA with...
Noxopharm advances Sofra platform as SOF-SKN nears FDA milestone
Jul 21, 2026
Noxopharm’s June quarter report highlights rapid progress across its Sofra platform, including new oligonucleotides that markedly boost Toll-like receptor 8 activity to enhance standard cancer therapies, positioning the company in a fast-exp...
Noxopharm moves SOF-SKN toward U.S. FDA pathway to boost autoimmune portfolio
Jul 6, 2026
Noxopharm has requested a pre-Investigational New Drug meeting with the U.S. Food and Drug Administration to discuss the clinical development pathway, manufacturing and quality controls for SOF-SKN, its autoimmune disease drug candidate. The meeti...
Noxopharm Sofra Platform Backed in $1m Grant for Childbirth Injury Treatment
Jul 1, 2026
Noxopharm’s strategic partner, Hudson Institute of Medical Research, has secured a $1 million Medical Research Future Fund grant for a three-year project using the company’s Sofra™ oligonucleotide platform to address childbirth-r...
Noxopharm unveils human-like TLR8 model to accelerate cancer immunotherapy program
Jul 1, 2026
Noxopharm has developed an advanced animal model intended to fast-track its immuno-oncology program by overcoming a longstanding obstacle in studying Toll-like receptor 8, a key target in its cancer research. Created in collaboration with the Huds...
Noxopharm Starts SOF-SKN Manufacturing Ahead of Cutaneous Lupus Trial
Jun 8, 2026
Noxopharm has begun manufacturing its SOF-SKN drug candidate to support a planned clinical trial later this year targeting cutaneous lupus erythematosus, a chronic autoimmune skin disease with limited targeted therapies. The manufacturing run, con...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.